Drugs / KD-496
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05583201 | Oct 2022 → Jun 2024 | gastric cancer, malignant pancreatic neoplasm | jianming xu | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06134960 | Nov 2023 → Jun 2026 overdue | gastric cancer, malignant pancreatic neoplasm | Peking University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD-496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134960 ↗ |
| Modality | Cell therapy | “NKG2D/CLDN18.2-based CAR-T cells infusion” NCT05583201 ↗ |